• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >The prognostic relevance and expression of progranulin in adult patients with acute myeloid leukemia
【24h】

The prognostic relevance and expression of progranulin in adult patients with acute myeloid leukemia

机译：急性髓性白血病成年患者植物素的预后相关性与表达

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Progranulin (PGRN) is a secreted protein that can regulate cell cycle progression, cell motility, and tumorigenesis. The PGRN expression in hematological malignancies is limited to multiple myeloma, but its expression and survival prognostic role in acute myeloid leukemia (AML) is still controversial. To evaluate the PGRN expression and estimate its survival prognostic role in AML patients. In this study, all patients were divided into three groups, which included 38 newly diagnosed adult AML patients, 33 complete remissions (CR-AML) patients, and 60 healthy control (HC) patients. The endpoints were relapse-free survival (RFS) and overall survival (OS). We investigated plasma PGRN levels by using enzyme-linked immunosorbent assay. Plasma PGRN levels in AML patients were higher than that in CR-AML and HC groups. After two chemo cycles, 16 patients had complete remission (CR). The level of plasma PGRN in non-CR patients compared to CR patients was obviously different (median 44.19 vs 21.10 ng/mL) ( P = .025). In non-M3 (French–American–British classification) patients, 70% (21/30) patients relapsed in 1 year and 80% (24/80) patients died in the observed time. Using the value (median 19.95) as a “cut-off” value, we have divided non-M3 patients into low- and high-PGRN expression groups. High-PGRN expression patients had a poorer RFS with a median of 5.4 months (95% CI 3.7–7.1) and low-PGRN expression patients had a good RFS with a median of 8.9 months (95% CI 6.3–11.5; P = .027). In the survival analyses, high-PGRN expression of AML patients had shorter OS than low-PGRN expression of AML patients (6.2 vs 20.5 months, P = .008). PGRN is overexpressed in AML, which is a convenient and independent prognostic marker that is measured easily in AML patients.
机译：Progranulin（PGRN）是一种分泌的蛋白质，其可以调节细胞周期进展，细胞运动和肿瘤率。血液恶性肿瘤中的PGRN表达仅限于多发性骨髓瘤，但其在急性髓性白血病（AML）中的表达和存活预后作用仍存在争议。评估PGRN表达并估计其在AML患者中的存活预后作用。在这项研究中，将所有患者分为三组，其中包括38名新诊断的成人AML患者，33例完整的剩余（CR-AML）患者和60例健康对照（HC）患者。终点是无复发存活（RFS）和总存活（OS）。我们通过使用酶联免疫吸附测定来研究血浆PGRN水平。 AML患者的血浆PGRN水平高于Cr-AML和HC组。经过两次化疗循环后，16名患者已完全缓解（CR）。与CR患者相比，非CR患者中血浆PGRN水平明显不同（中位数44.19 vs 21.10ng / ml）（p = .025）。在非M3（法国美式 - 英国分类）患者中，70％（21/30）患者在1年复发，80％（24/80）患者在观察到的时间死亡。使用价值（中位数19.95）作为“截止”值，我们将非M3患者分为低和高PGRN表达组。高分子表达患者的RFS具有5.4个月中位数（95％CI 3.7-7.1），低PGRN表达患者的良好RFS具有8.9个月的中位数（95％CI 6.3-11.5; P =。 027）。在存活分析中，AML患者的高分PGRN表达比AML患者的低植物表达更短的OS（6.2 Vs 20.5个月，P = .008）。 PGRN在AML中过表达，这是一种方便且独立的预后标记，可在AML患者中轻松测量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号